Artal Group S.A. Akebia Therapeutics, Inc. Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$2.39 - $13.08 $1.37 Million - $7.51 Million	-574,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $993,830 - $2.02 Million	149,000 Added 35.06%	574,000 $7.8 Million
Q2 2019 Aug 09, 2019	SELL	$4.1 - $8.05 $204,999 - $402,500	-50,000 Reduced 10.53%	425,000 $2.06 Million
Q1 2018 May 10, 2018	BUY	$9.53 - $15.68 $4.53 Million - $7.45 Million	475,000 New	475,000 $4.53 Million

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $346M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.